Valentina Pettirossi

Perugia, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor.

The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor.

Journal: Leukemia
Published: October 04, 2022

Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients.

Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients.

Journal: Blood cancer discovery
Published: June 24, 2021

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.

Journal: Leukemia
Published: November 19, 2020

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Journal: Blood
Published: November 06, 2017

Genomics of Hairy Cell Leukemia.

Genomics of Hairy Cell Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 16, 2017

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

Journal: Blood
Published: December 07, 2014

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.

Journal: Blood
Published: November 19, 2014

Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.

Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.

Journal: Haematologica
Published: January 26, 2013

Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia.

Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia.

Journal: Blood
Published: June 02, 2012
Showing 1-9 of 9

Last Updated: 09/26/2026